Urology Times Newsletter

FOCUS ON: PROSTATE CANCER

Role and rationale for molecular testing in advanced prostate cancer

Advances in genomic testing will help determine lines of therapy in men with mCSPC and mCRPC, according to Raoul S. Concepcion, MD.

Read his article

Hydrogel spacer lowers rectal bleeding vs. balloon immobilization treatment

Results from 2 years of follow-up in men undergoing proton beam therapy for localized prostate cancer suggest that treatment with the rectal hydrogel spacer (SpaceOAR) provides better rectal sparing than rectal balloon immobilization.

Learn more

5-year cancer control comparable for focal therapy, RP

A multicenter study in the United Kingdom found 5-year prostate cancer control rates following treatment with focal therapy are similar to those of patients who have undergone radical prostatectomy, even when accounting for variation in tumor location, size, and risk.

Get the data